Aligos Therapeutics Inc
NASDAQ:ALGS
Intrinsic Value
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. [ Read More ]
The intrinsic value of one ALGS stock under the Base Case scenario is 1.51 USD. Compared to the current market price of 0.75 USD, Aligos Therapeutics Inc is Undervalued by 50%.
Valuation Backtest
Aligos Therapeutics Inc
Run backtest to discover the historical profit from buying and selling ALGS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Aligos Therapeutics Inc
Current Assets | 141.1m |
Cash & Short-Term Investments | 135.7m |
Other Current Assets | 5.4m |
Non-Current Assets | 10.4m |
PP&E | 9.8m |
Other Non-Current Assets | 625k |
Current Liabilities | 23.9m |
Accounts Payable | 2.5m |
Accrued Liabilities | 17m |
Other Current Liabilities | 4.3m |
Non-Current Liabilities | 35.5m |
Long-Term Debt | 231k |
Other Non-Current Liabilities | 35.3m |
Earnings Waterfall
Aligos Therapeutics Inc
Revenue
|
15.5m
USD
|
Operating Expenses
|
-103.7m
USD
|
Operating Income
|
-88.1m
USD
|
Other Expenses
|
448k
USD
|
Net Income
|
-87.7m
USD
|
Free Cash Flow Analysis
Aligos Therapeutics Inc
What is Free Cash Flow?
ALGS Profitability Score
Profitability Due Diligence
Aligos Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Aligos Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
ALGS Solvency Score
Solvency Due Diligence
Aligos Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Aligos Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALGS Price Targets Summary
Aligos Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for ALGS is 4.08 USD with a low forecast of 1.01 USD and a high forecast of 7.35 USD.
Ownership
ALGS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ALGS Price
Aligos Therapeutics Inc
Average Annual Return | -22.45% |
Standard Deviation of Annual Returns | 90.41% |
Max Drawdown | -98% |
Market Capitalization | 56.8m USD |
Shares Outstanding | 75 670 000 |
Percentage of Shares Shorted | 1.27% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 93 full-time employees. The company went IPO on 2020-10-16. The firm is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. The company uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. The company is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). The company developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The firm's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.
Contact
IPO
Employees
Officers
The intrinsic value of one ALGS stock under the Base Case scenario is 1.51 USD.
Compared to the current market price of 0.75 USD, Aligos Therapeutics Inc is Undervalued by 50%.